Identification of New Inborn Errors of Immunity

Launched by UNIVERSITY OF ZURICH · Jan 22, 2018

Keywords

ClinConnect Summary

This clinical trial is focused on understanding a group of conditions known as primary immune deficiency disorders (PID), which affect how the immune system works. Researchers are looking at DNA samples from patients who have been diagnosed with PID but where the exact cause is still unknown. By using advanced techniques to analyze their genetic material, the goal is to identify new types of immune deficiencies that have not been previously recognized. This study is currently recruiting participants of all ages, from newborns to adults, and both males and females are welcome to join.

To participate, individuals must have a confirmed diagnosis of primary immune deficiency and provide written consent to be part of the study. Those with secondary immune deficiencies, which are caused by external factors like infections or medications, are not eligible. Participants in the trial can expect to undergo genetic testing, which might help doctors learn more about their condition and how to improve treatment in the future. This research is important because it could lead to new insights into immune disorders and enhance the care for patients affected by these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with primary immunodeficiency (PID)
• • Male and Female participants 0 years to adult age (any)
• • Written informed consent by the participant after information about the research project
• Exclusion Criteria:
• • Secondary immunodeficiency
• • Refusal to enter the study